Major advances in molecular biology and in genetics and genomics during the last several years now present unique opportunities for enhancing our understanding of human physiology and disease predisposition. From the endocrinologist's perspective, there is the potential not only for new hormones to be discovered and characterized, but also the unprecedented possibility of gaining novel insights into endocrine pathophysiology and disease mechanisms. A first step in taking advantage of these opportunities is to access publicly available databases. A wealth of information is available in these repositories; however, the volume of data is potentially overwhelming, and the ability to extract, catalog, evaluate the quality, and assess and interpret the information can be challenging. Despite these difficulties, the value of the data is potentially high because new research questions can be shaped and defined, leading to insights that may be actionable in terms of addressing important biomedical problems. For example, genome sequencing on a large scale has the potential to provide novel ideas about human disease susceptibility, and to shed light on human evolution and population variation ([@B1]--[@B4]).

In this mini-review, I demonstrate the power of close examination and analysis of genomic information in providing new understanding of endocrine systems. My illustrative example is the human growth hormone (GH) signaling pathway for the reasons subsequently outlined.

GH Signaling and Actions {#s1}
========================

GH plays a pivotal role in multiple physiologic processes in humans and other mammals. It is not only essential for somatic growth during childhood through its induction of insulinlike growth factor-1 (IGF1), but additionally it is an important regulator of intermediary metabolism and tissue repair throughout life ([@B5],[@B6]). GH actions also have a dark side because they have been implicated in the development of certain cancers and in the pathophysiology associated with aging ([@B7]--[@B9]). Like related hormones and cytokines, GH acts after binding to a transmembrane receptor ([@B10]). Ligand binding to the growth hormone receptor (GHR) activates several signaling pathways ([@B5],[@B10],[@B11]). Among the most important is the just another kinase (JAK)--signal transducer and activator of transcription (STAT) cascade, in which induction of tyrosine kinase activity of JAK2 ([@B5],[@B10],[@B11]) causes phosphorylation of tyrosine residues on the intracellular part of the GHR ([@B5],[@B11]), leading to recruitment of several signaling molecules, including STATs. The seven members of the STAT family are inducible transcription factors that function as effectors of activated cytokine and growth factor receptors ([@B12],[@B13]). STAT5B in particular is a critical component of GH actions, being responsible for GH-stimulated production of IGF1 by promoting its gene transcription ([@B14]--[@B16]).

Decreased activity through the GH-IGF1 axis causes growth defects in humans that result in short stature ([@B17]--[@B19]). A variety of human genetic abnormalities have been shown to impair GH messenger RNA expression or protein biosynthesis \[specifically the*GH1* gene ([@B20],[@B21])\], and mutations in the*GHR* have been described that reduce its synthesis or biological actions ([@B22]). A few individuals also have been reported with growth deficiency and inactivating mutations in the*IGF1* or*IGF1 receptor* genes ([@B23],[@B24]), or in*STAT5B* ([@B25]).

Database Mining and Analysis {#s2}
============================

DNA sequence information from the Exome Aggregation Consortium (ExAC) ([@B26]--[@B30]) comprises the primary data source for this mini-review (<http://exac.broadinstitute.org/>), and consists of results of exome sequencing from 60,706 different individuals. Other information was obtained from the following resources: human messenger RNAs and genes from the Ensemble Genome Browser, genome assembly GRCh38 ([www.ensemble.org](http://www.ensemble.org)) ([@B31]); and human protein sequences from the Uniprot browser (<http://www.uniprot.org/>), and from the National Center for Biotechnology Information Consensus CDS Protein Set (<https://www.ncbi.nlm.nih.gov/CCDS/>). The mutations in human*GH*,*GHR*,*JAK2*, and*STAT5B* reported in[Tables 2](#T2){ref-type="table"} and[3](#T3){ref-type="table"} are from Online Mendelian Inheritance in Man (<https://www.omim.org/>), which is a compendium of human genes and genetic conditions (and has an excellent online tutorial for those who wish to learn how to use it), and the Growth Genetics Consortium (<http://www.growthgenetics.com/>). Among other useful resources for studying genetic connections with endocrine and other diseases are the following: the GWAS catalog (<https://www.ebi.ac.uk/gwas/>) contains a manually curated collection of published genome-wide association studies, and is searchable by disease, gene name, author, single nucleotide polymorphism, or human chromosomal location. COSMIC (<http://cancer.sanger.ac.uk/cosmic>) consists of a compendium of cancer mutations, and can be searched by gene name, cancer type, cancer site, molecule, author, single nucleotide polymorphism, and other topics.

ExAC contains DNA sequencing results from the exons of genes of 60,706 people, and has been available publicly for less than a year ([@B26]). These individuals live in various parts of the world, and have different ethnic backgrounds. Their overall health status is unknown ([@B26]). Among the general conclusions from the initial published analysis of these 121,412 alleles is that variation within the coding regions of human genes is extensive ([@B26]). It appears however that most of the detected modifications are uncommon, with over half being seen in a single allele, and \>99% being found in \<1% of the ExAC population ([@B26]). Also, most the observed differences among people studied appear to consist of synonymous nucleotide changes or amino acid substitutions ([@B26]), with only the latter altering protein sequence. However, it seems likely that the extent of variation may differ significantly for individual human genes, and more importantly, that there may be substantial variability among components of pathways in which certain of the encoded proteins act. Hence, the analysis of the human GH signaling cascade presented here, which serves as an illustrative example of how such publicly available databases can be assessed to gain new insights into human endocrine physiology.

Allelic Variation in GH Signaling Molecules in Humans {#s3}
=====================================================

Examination of the genes for GH signaling molecules in ExAC reveals a wide range of coding variation, with most changes in*GH1*,*GHR*,*JAK2*, and*STAT5B* being missense mutations (94% to 97%) ([Table 1](#T1){ref-type="table"}). Second most common were alterations in the protein reading frame, including addition of truncating stop codons (\~2% to 4%) ([Table 1](#T1){ref-type="table"}). The total number of different alleles per gene varied by more than threefold, from 101 for*GH1* to 338 for*JAK2*. When corrected for protein length, protein modifications also varied by a factor of 3, from 0.14 nonsynonymous changes/codon for*STAT5B*, to 0.47 for*GH1* ([Table 1](#T1){ref-type="table"}). In terms of prevalence in the study population, 98% of missense alleles were found in \<0.1% of individuals, and 99.6% were detected in \<1.0%. These results show that overall variation in GH signaling proteins is low in this study group, and is consistent with general conclusions from the initial analysis of ExAC data ([@B26]).

###### 

Human Population Variation in*GH1*,*GHR*,*JAK2*, and*STAT5B*

  **Protein**   **No. of Codons** [***^a^***](#t1n1){ref-type="table-fn"}   **Missense and In-Frame Insertions-Deletions**   **Frame Shifts, Stop Codons**   **Splicing Site Changes**   **Loss of Start Codon**   **Loss of Stop Codon**   **Total No. of Different Changes**   **Variants per Codon**   **Total Variant Alleles in Population (%)**
  ------------- ----------------------------------------------------------- ------------------------------------------------ ------------------------------- --------------------------- ------------------------- ------------------------ ------------------------------------ ------------------------ ---------------------------------------------
  GH            217                                                         96                                               4                               1                           0                         0                        101                                  0.47                     1.4
  GHR           638                                                         229                                              8                               6                           1                         0                        244                                  0.38                     53.9
  JAK2          1132                                                        327                                              6                               5                           0                         0                        338                                  0.29                     2.6
  STAT5B        787                                                         104                                              4                               0                           0                         0                        108                                  0.14                     0.4

Based on transcripts used in ExAC database. One predicted variant does not correspond with the amino acid sequence of GHR and is not included in the compiled data.

Splicing changes at exon-intron and intron-exon junctions, reading frame alterations caused by insertions or deletions of DNA, and nucleotide changes that lead to the addition of stop codons each can contribute to loss of protein expression. The number of alleles showing these changes was very low among GH signaling genes, comprising a handful of different instances that were rare in the study population (0.007% to 0.11% allelic frequency). Copy number variation, in which a gene is absent or is present in more than one copy per chromosome, was similarly infrequent, and ranged from no instances for*GH1* and*GHR*, to two for*STAT5B* and 42 for*JAK2*.

Population Variation in GH {#s4}
==========================

*GH1* resides on chromosome 17q23.3 in a cluster of five related genes that include two genes coding for placental lactogen (chorionic somatomammotropin), one encoding a placental lactogen analog, and the other encoding the GH gene variant,*GH2* ([@B32]), which unlike*GH1*, is minimally expressed in the pituitary gland ([@B32]). The first characterized mutations in*GH1* were gene deletions in individuals with familial GH deficiency ([@B33]), and multiple instances of gene and partial locus deletions have been described subsequently ([@B34],[@B35]). Later studies identified individuals with short stature, who had presumptive inactivating amino acid changes in*GH1* exons, or who had frame shift mutations or stop codons that prevented full-length GH from being synthesized in pituitary somatotrophs ([@B34],[@B35]). Listed in[Table 2](#T2){ref-type="table"} are eight such previously characterized mutations, and their prevalence in the ExAC population. Alterations at four of these sites are present in ExAC, but are rare, because only one substitution, I^205^\>M, is detected as frequently as \~0.04% of the population (56 alleles), and the other three are found in \<1 in 10,000 chromosomes ([Table 2](#T2){ref-type="table"}).

###### 

Disease-Associated Mutations in*GH1* and*GHR*

  **Mutation**    **Population Variant**      **ExAC Prevalence**
  --------------- --------------------------- ---------------------
  *GH1*                                       
   W20stop        None                        ---
   E58K           None                        ---
   C79S           C79fs                       1 Allele
   R103C          R103H                       1 Allele
   D138G          None                        ---
   G157fs         G157D                       13 Alleles
   I205M          I205M                       56 Alleles
   R209H          None                        ---
  *GHR*                                       
   W4stop         None                        ---
   W34stop        None                        ---
   C56stop        C56stop                     1 Allele
   R61stop        R61stop, R61G, R61L, R61Q   2, 1, 1, 10 Alleles
   Q83stop        Q83L                        1 Allele
   W98stop        None                        ---
   C101stop       None                        ---
   Y113stop       None                        ---
   V143Lfs        V143I                       2 Alleles
   L159stop       None                        ---
   W175stop       None                        ---
   E198splice     None                        ---
   V199-M206del   V199A, V199I                6, 1 Alleles
   E201stop       E201G                       2 Alleles
   M206-M207ins   None                        ---
   M207Ifs        M207V                       2 Alleles
   R235stop       R235stop                    1 Allele
   E242stop       E242D, E242K                3, 7 Alleles
   I293Kfs        I293Kfs                     1 Allele
   I297Kfs        None                        ---
   V301Sfs        V301I                       1 Allele
   I328Pfs        I328T                       2 Alleles
   A442Sfs        None                        ---
   C56S           None                        ---
   S58L           None                        ---
   E60K           E60K                        1 Allele
   E62K           E62K                        3 Alleles
   W68R           None                        ---
   R89K           None                        ---
   Y104D          None                        ---
   C112S          None                        ---
   F118S          None                        ---
   Q148P          None                        ---
   V162I          V162I, V162F                166, 17 Alleles
   H168Q          H168Q, H168P                1, 2 Alleles
   D170H          None                        ---
   I171T          None                        ---
   Q172P          None                        ---
   V173G          None                        ---
   R179C          R179C, R179H                496, 36 Alleles
   Y226C          Y226F                       1 Allele
   R229H, G       R229H, R229C, R229L         159, 3, 1 Alleles
   S244I          None                        ---
   D262N          None                        ---
   L544I          L544I                       67,843 Alleles

Two predicted alterations in mature GH, A^39^\>V and V^136^\>I, account for over half of all population changes among ExAC alleles \[[Fig. 1(a)](#F1){ref-type="fig"};[Table 1](#T1){ref-type="table"}\]. Remarkably A^39^\>V maps to site 1, one of two three-dimensional recognition domains that mediate binding of one molecule of GH to two molecules of the GHR ([@B36]) \[site 1 comprises amino acids F^36^ to M^40^, F^80^ to Q^94^, and D^195^ to V^206^, and site 2 comprises amino acids F^27^ to R^34^ and D^142^ to E^145^ ([@B36],[@B37])\]. Experiments now may be performed to address whether the valine side chain at position 39 could alter hormone-receptor recognition, and thus influence GH-mediated receptor activation. There are other predicted amino acid substitutions in the GH molecule, such as those associated with growth defects as previously noted ([Table 2](#T2){ref-type="table"}), but these occur with allelic frequencies that seem too low (from 1 in 2500 to 1 in 120,000) to have an appreciable population impact on human physiology.

![Population variation in human GH signaling molecules. (a) The human GH precursor consists of a 26-amino acid (AA) signal peptide (SP) and the 191-residue mature protein. The 20-kDa variant GH found in the blood lacks AAs 58 to 72 (Δ58-72 in the diagram). The overall population prevalence of variant alleles for each segment of pre-GH is listed below the map, and the location and prevalence of the two most common variants are depicted in single letter AA code. The scale bar represents 20 AAs. (b) The human GHR precursor consists of an 18-residue SP and the 620-AA mature protein. Major parts of the mature receptor are indicated. The overall population prevalence of variant alleles for the SP and for mature GHR is listed below the map, and the location and prevalence of the three most common variants is depicted in single letter AA code. The scale bar represents 100 AAs. (c) Diagram of 1132-AA human JAK2, with different domains indicated. The overall population prevalence of variant alleles is listed below the map, and the location of the three most common variants is depicted in single letter AA code. The scale bar represents 200 AAs. FERM, residues 37 to 380; PK1, pseudoprotein kinase domain, residues 545 to 809; PK2, protein kinase domain, AAs 849 to 1124; S, SH2 domain, AAs 401 to 482.](en.2017-00338f1){#F1}

Variability in the GHR {#s5}
======================

The GHR was the first member of the cytokine receptor family to be characterized, and was among the first receptors to be shown to engage the JAK-STAT signaling cascade ([@B5],[@B10],[@B11],[@B38]). Many different mutations in the*GHR* gene have been associated with human growth deficiency syndromes ([@B17],[@B22],[@B39]). Even though the first subject to be characterized molecularly had a complex rearrangement within the*GHR* locus on chromosome 5p13-p12 ([@B40]), most mutations identified to date are splicing alterations, protein truncating stop codons, or amino acid substitutions ([@B17],[@B22],[@B39]) ([Table 2](#T2){ref-type="table"}). Of the 23 different disease-associated frame shifts, stop codons, and splicing mutations listed in[Table 2](#T2){ref-type="table"}, only four are found in the ExAC database, with all being present at very low frequencies (C^56^stop, one allele; R^61^stop, two alleles; R^235^stop, one allele; I^293^\>K-frame shift, one allele). In addition, amino acid substitutions at the same locations as the frame shifts and stop codons in the*GHR* gene also are rare, being detected at allelic frequencies of \<0.01% in the population ([Table 2](#T2){ref-type="table"}).

Of 22 different disease-associated amino acid substitution locations in the GHR, only eight are present in the ExAC database ([Table 2](#T2){ref-type="table"}). Most changes that are connected to GHR dysfunction and growth defects map to the extracellular domain of the receptor ([@B17],[@B22],[@B39]), and five of these disease-linked alterations are very uncommon in the general population, being found in only one or three alleles of \>121,000 surveyed ([Table 2](#T2){ref-type="table"}). However, two changes are present in \~0.1% of chromosomes (V^162^\>I and R^229^\>H, 166 and 149 alleles, respectively) and one in \~0.4% (R^179^\>C, 496 alleles). The high prevalence of these three substitutions suggests either that the modifications may not be disease causing or that potentially subtle differences in the ability of the GHR to bind GH may be polymorphic in the human population. Further, one presumptive amino acid change in the intracellular region of the GHR that has been associated with growth impairment, L^544^\>I, is actually the most common allele in ExAC, being found in 56% of all chromosomes sequenced (67,843 alleles) ([Table 2](#T2){ref-type="table"}). The other polymorphic allele accounts for the remaining 44% of chromosomes in the population \[[Fig. 1(b)](#F1){ref-type="fig"}\]. Similarly, two other amino acid substitutions in the intracellular part of the GHR that were each first identified in an individual with a Laron-type syndrome of short stature and lack of response to GH treatment, C^440^\>T and P^579^\>T ([@B41]), are found in 4% of the population \[[Fig. 1(b)](#F1){ref-type="fig"}\]. Thus, it seems likely that these latter modifications are also polymorphic variants. Of note, none appears to map to segments of the GHR that have been found previously to be critical for signal transduction ([@B42]--[@B44]). Experiments now may be designed to assess their effects on receptor function.

Population Aspects of JAK2 and STAT5B {#s6}
=====================================

JAK2 is one of four members of a nonreceptor tyrosine kinase family that also includes JAK1, JAK3, and Tyk2 ([@B45]). All these molecules function as obligate protein kinases for multiple cytokine receptors ([@B46],[@B47]). Seven different amino acid substitution mutations in JAK2 have been described in individuals with blood dyscrasias, including polycythemia vera, thrombocythemia, and myelofibrosis, and several classes of leukemia ([@B48]--[@B52]), but no abnormalities in JAK2 have been associated with growth disorders in humans. Of these disease-linked alterations, only V^617^\>F is detected in ExAC, and surprisingly is present in 0.07% of chromosomes (82 alleles) ([Table 3](#T3){ref-type="table"}), perhaps indicating that a predisposition to one of these precancerous diseases is prevalent among different human populations.

###### 

Disease-Associated Mutations in*JAK2* and*STAT5B*

  **Mutation**   **Population Variant**    **ExAC Prevalence**
  -------------- ------------------------- ---------------------
  *JAK2*                                   
   K539L         None                      ---
   K607N         None                      ---
   V617F, I      V617F                     82 Alleles
   R683G, K, S   None                      ---
  *STAT5B*                                 
   L142Rfs       None                      ---
   R152stop      R152P, R152Q              1, 6 Alleles
   Q368fs        Q368K, Q368Pfs, Q368Rfs   2, 91, 41 Alleles
   N398fs        None                      ---
   E561Rfs       None                      ---
   A630P         None                      ---
   F646S         None                      ---

Overall, variant alleles are found in*JAK2* in 2.6% of the population ([Table 1](#T1){ref-type="table"}), with three substitutions, G^127^\>D, L^393^\>A, and R^1063^\>H, accounting for half of the changes \[[Fig. 1(c)](#F1){ref-type="fig"}\]. The biological significance of these three modifications is unknown. Although they are found in different domains of the protein \[[Fig. 1(c)](#F1){ref-type="fig"}\], none map to segments of the molecule involved in signaling with either the GHR or other cytokine receptors ([@B11],[@B53]).

STAT5B, a 787-amino acid protein ([@B54]), is a critical transcription factor for GH-activated*IGF1* gene expression ([@B14]--[@B16]), and mutations in human STAT5B phenocopy GH and GHR deficiencies regarding growth deficits; however, most of the handful of individuals found to have inactivating*STAT5B* gene alterations also presented to medical attention with evidence of immune system defects ([@B25]). Compared with the other genes studied here,*STAT5B* is an outlier because its extent of variation in the population (0.4%, 0.14 changes per codon) was much lower than was detected for*GH1*,*GHR*, or*JAK2* ([Table 1](#T1){ref-type="table"}). Additionally, no amino acid substitution or frame shift mutation was present in \>0.08% of chromosomes ([Table 3](#T3){ref-type="table"}). Although speculative, perhaps the minimal level of variability in the*STAT5B* gene reflects its multifactorial role as a signal transducer for GH, prolactin, erythropoietin, and multiple other cytokines ([@B13],[@B46],[@B54]).

As noted, a small number of humans have been identified with*STAT5B* gene mutations ([@B19],[@B25]). In all cases, these individuals have been ascertained because of severe growth failure associated with evidence of immune deficiency ([@B19],[@B25]), and of these, two are single amino acid changes and five are frame shift mutations or stop codons ([Table 3](#T3){ref-type="table"}). Alterations at two of these sites are present in the ExAC database, with predicted amino acid substitutions at the Q^368^ frame shift location being present in \~0.1% of chromosomes in the population (132 alleles) ([Table 3](#T3){ref-type="table"}). The other mutations are either very rare or absent in ExAC ([Table 3](#T3){ref-type="table"}).

Limitations and Strengths of Population-Based Genome Sequence Data in Understanding GH Actions in Humans {#s7}
========================================================================================================

As potentially expected with any large-scale DNA sequencing project, the ExAC database contains extensive material for novel biological insights, and both ambiguities and errors. From the perspective of GH signaling and actions, potential problems include the presence of at least one presumptive polymorphic coding variant that cannot be mapped to the*GHR* gene or protein. Other limitations of the data include the potential skewing of the study population. Although several different groups are represented, \>60% of samples derive from Europeans, \~20% are East or South Asian, and only \~8% are either of Hispanic or African origin ([@B26]). Thus, the true rate and extent of variation among proteins in humans may not be established yet. In addition, there is a likely error rate associated with the many nucleotide changes that appear only once in 121,412 chromosomes evaluated.

Despite these limitations, these data provide a multitude of new opportunities to understand and reconsider what is normal GH physiology and to redefine the extent of its pathophysiology in humans. GH actions are critical for normal somatic growth in children, with growth rates functioning as a possible readout for dynamic interactions between genetic and environmental factors ([@B55]). These interactions, and the range of outcomes labeled normal, now may be reassessed in the context of many versions of GH and the GHR in the population. GH actions also have been postulated to be involved in aging ([@B9]) and in cancer pathogenesis ([@B7],[@B8]), and the hypothesis now may be considered that some variants of either GH or the GHR, or specific combinations with different types of JAK2 or STAT5B, may enhance disease susceptibility, whereas others may be protective. A similar perspective on variation in insulinlike growth factor signaling and action, and its roles in human physiology and disease, has recently been published ([@B56]).

The extensive variability captured by ExAC should be traceable to our ancestors, including extinct populations ([@B57],[@B58]). Modern humans contain marks in their DNA of past contacts with these populations, including both Denisovans and Neanderthals, and the legacy of these interactions still influences some traits and probably some disease susceptibilities ([@B58]). New hypotheses inspired by the data from ExAC and other genome sequencing projects could lead to novel insights about how the complex biology of GH actions has been shaped over millennia. Similar opportunities to develop new research questions and to define new physiologic paradigms exist for other areas of endocrinology, and should incentivize investigators to extract, critically evaluate, and interpret these data.
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